| 摘要 |
The disclosure relates to the use of a purified or isolated angeloyl substituted ingenane, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cancer growth or for preventing or reducing metastasis of a cancer growth, where, in the case of treating a cancer growth, the medicament is formulated for administration directly or proximally to a cancer distant to said cancer growth; or in the case of preventing or reducing metastasis of a cancer growth, the medicament is formulated for administration directly or proximally to said cancer growth, and wherein said medicament induces necrosis in at least the cancer cells and stimulates the generation of cancer specific T-cells.
|
